# A Trial of SHR-A2102 With Antitumor Therapy in Advanced Urothelial Carcinoma

Source: https://onco.cc/trials/nct06639347/  
OnCo record `nct06639347` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of SHR-A2102, Adebrelimab and SHR-8068 in bladder & urothelial cancer, run by Shanghai Hengrui Pharmaceutical Co., Ltd., now recruiting.

## Summary

A Trial of SHR-A2102 With Antitumor Therapy in Advanced Urothelial Carcinoma is a phase 1/2 interventional study registered as NCT06639347 by Shanghai Hengrui Pharmaceutical Co., Ltd., with 90 participants planned, started 2024-11-04 and due to reach its primary completion in 2027-05-31. Interventions recorded: SHR-A2102, Adebrelimab injection and SHR-8068 injection.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06639347
- Phase: 1/2
- Setting: An Open Label, Multicenter, Phase Ib/Il Study to Evaluate the Safety, Tolerability, and Efficacy of SHR A2102 in Combination With Other Anti-cancer Agents in Patients With Advanced Urothelial Carcinoma
- Sponsor: Shanghai Hengrui Pharmaceutical Co., Ltd.
- Enrolled: 90

## Sources

- ClinicalTrials.gov NCT06639347: https://clinicaltrials.gov/study/NCT06639347

## Connected records

- cancers: [Bladder & urothelial cancer](https://onco.cc/cancers/urothelial/)
- drugs: [Adebrelimab](https://onco.cc/drugs/adebrelimab/), [SHR-8068](https://onco.cc/drugs/shr-8068/), [SHR-A2102](https://onco.cc/drugs/shr-a2102/)
- companies: [Jiangsu Hengrui Pharmaceuticals](https://onco.cc/companies/hengrui/)

---
JSON: https://onco.cc/api/v1/entities/nct06639347.json